Claim 1: Heteroantibody or fragment containing one or more substitutes in the following fields: the first domain ch832323；Second areaA month agoA Cl domain, a VH domain and a VL domain, in which one or more substitutes introduce charged amino acids, which are not conducive to the formation of heterosexual favorable homologues and voltages. Claim 25: a heterosexual antibodyFragments that are irritable or consist of a heavy chain, including (a) the first substitution of amino acids at a selected aho location within the group, which consists of an aho 42-50 location, into which the amino acids loaded at that location are entered(b) A second substitution of the amino acid at the selected position in the group consisting of positions 126-213 (EU number), which inputs the loaded amino acid into the position, (c) The third position in the group consisting of 352-360 position (EU number) replaces the amino acid, which inputs the loaded amino acid into the position, Y (d) replaces the amino acid for the fourth time at the selected position in 395-403 (EU No.) position group, where a loaded amino acid is input,The amino acids loaded with (a) have the same load as those loaded with (b), and the amino acids loaded with (c) and (d) have the opposite load as those loaded with (a) and (b). Claim 57: a nucleic acid, comprising a series of nucleic acids, encoding an abiotic antibody according to any of claims 1-56. Ravin Dickie60th reaction: methods to increase bone mineral density in mammalian body, including effective management of different antibodies according to any needs of subjects 1-56, in order to increase bone mineral density of subjects. Requirement 65: components consisting of heteromorphic antibodies or their fragments and carriers1. The diluent or pharmaceutically acceptable adyuvante, wherein the isomerized antibody or its fragment includes one or more substitutes in each of the following fields: the first domain ch-832323；Second areaA month agoa CL domain, a VH domai
